Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.
Rejili. Mokhtar M; Hussain. Md Sadique MS; Khan. Yumna Y; Haouala. Faouzi F; Gan...
Error: Malformed JSON response.
Cagrilintide
AM-833, Long-acting amylin analogue
A long-acting amylin receptor agonist used for obesity and type 2 diabetes treatment by enhancing satiety, reducing food intake, and aiding weight loss.
Molecular Profile
Formula
C194H312N54O59S2
Mol. Weight
4409.01 g/mol
Sequence
Gly-Glu-Pro-Pro...
| Route | |
|---|---|
|
Subcutaneous (SC)
1.2-4.5 mg weekly
|
How It Works
How It Works: Cagrilintide is a long-acting analog of amylin that mimics its physiological effects to promote satiety and regulate metabolism, primarily used for weight management.
- Amylin Receptor Activation: Binds to calcitonin and amylin receptors in the brain to enhance feelings of fullness and reduce appetite.
- Gastric Emptying Inhibition: Slows the rate of gastric emptying, prolonging post-meal satiety.
- Glucose Homeostasis: Improves postprandial glucose control by modulating insulin and glucagon secretion.
- Synergistic Effects: Enhances weight loss when combined with GLP-1 receptor agonists like semaglutide.
Latest Clinical Trials
See All Clinical Trials
Recruiting
PHASE1
NCT06719011
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT07220642
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE1
NCT06144684
A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
AbbVie
INTERVENTIONAL
Updated Dec 15, 2025
Latest Studies
See All StudiesCagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.
Verma. Subodh S; Böttcher. Morten M; Brown. Paul P; Dicker. Dror D; Rubino....
In a 68‑week study of people with overweight or obesity (but no diabetes), a weekly injection that mixes two peptides—semaglutide and cagrilintide (called CagriSema)—cut systolic blood pressure by about 11 mm Hg and diastolic pressure by about 5 mm Hg, far more than a placebo. About two‑thirds of participants on CagriSema hit the blood‑pressure goals, versus one‑third on placebo, and many were able to cut back or stop their other blood‑pressure medicines.
Nutritional Challenges in Post-Massive Weight Loss Body Contouring: Guidance for Plastic Surgeons on GLP-1 Agonists and Sleeve Gastrectomy.
Mehta. Meeti M; Rometo. David D; Gusenoff. Jeffrey J; Rubin. J Peter JP
The paper talks about how people who lose a lot of weight after bariatric surgery often have trouble getting enough protein and vitamins, especially if they are also taking appetite‑suppressing drugs like semaglutide or tirzepatide. It gives surgeons advice on how to make sure these patients eat enough protein and fix nutrient gaps before and after body‑contouring surgery.